<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661346</url>
  </required_header>
  <id_info>
    <org_study_id>15-0309</org_study_id>
    <nct_id>NCT03661346</nct_id>
  </id_info>
  <brief_title>Esmolol vs. Labetalol in Endoscopic Sinus Surgery</brief_title>
  <official_title>Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative
      visibility scores in functional endoscopic sinus surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Improved intraoperative visibility during functional endoscopic sinus surgery
      (FESS) decreases the risk of serious orbital or skull base injuries. Beta blockers are among
      several methods used to reduce mean arterial pressure (MAP), heart rate (HR) and mucosal
      bleeding. Labetalol (mixed alpha-1-beta blocker) reduces HR and MAP; however, its alpha-1
      blockade may mitigate topical epinephrine decongestant effects. Esmolol (selective beta-1
      blocker) does not have direct antagonistic effects on topical epinephrine. This study
      compares the hemodynamic parameters (rate of blood loss, MAP control, HR) and intraoperative
      visibility during FESS between esmolol and labetalol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-operative surgical visibility - Boezaart scale</measure>
    <time_frame>Duration of operation</time_frame>
    <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:
Boezaart scale (0-5):
0 = no bleeding (optimal)
= slight bleeding with no suction required
= slight bleeding with occasional suctioning required
= slight bleeding with frequent suctioning required
= moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed
= severe bleeding (worst) with constant suctioning required and compromised view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-operative surgical visibility - Wormald scale</measure>
    <time_frame>Duration of operation</time_frame>
    <description>Standardized scoring systems used by surgeons to rate surgical field quality in FESS:
Wormald scale (0-10):
0 = No bleeding (optimal)
= 1-2 points of blood ooze
= 3-4 points of ooze
= 5-6 points of ooze
= 7-8 points of ooze
= 9-10 points of ooze
= &gt;10 points of ooze, obscuring field
= Mild field bleeding with slow post-nasal accumulation
= Moderate field bleeding with moderate post-nasal accumulation
= Moderate-severe field bleeding with rapid post-nasal accumulation
= Severe bleeding (worst) with nose filling rapidly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of blood loss</measure>
    <time_frame>Duration of operation</time_frame>
    <description>milliliters per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average mean arterial blood pressure</measure>
    <time_frame>Duration of operation</time_frame>
    <description>units of mmHg, measured throughout operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average heart rate</measure>
    <time_frame>Duration of operation</time_frame>
    <description>units of beats per minute, measured throughout the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving esmolol when intra-operative MAP &gt; 80 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving labetalol when intra-operative MAP &gt; 80 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Aliquots of 20mg of Labetol
• Maximum Dose - 300mg total for case</description>
    <arm_group_label>Labetalol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Infusion - 0.1mg/kg/min
• Maximum Dose - after 30 minutes, 0.3mg/kg/min</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of CRS with or without nasal polyps

          -  Undergoing FESS for CRS

          -  American Society of Anesthesiologists (ASA) physical status 1 (healthy) or 2 (patient
             with mild systemic disease).

        Exclusion Criteria:

          -  Pregnancy

          -  Asthma

          -  COPD

          -  Bradycardia

          -  Heart failure

          -  End stage renal disease

          -  Cerebrovascular accident

          -  Diabetes mellitus

          -  Preoperative use of NSAIDs, aspirin, or beta-blockers

          -  Body mass index (BMI) greater than 40 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Chaaban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3 months to 3 years at time of publication (if applicable)</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03661346/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>May 20, 2019</submitted>
    <returned>June 13, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

